Trulieve Receives First DEA Registrations as Federal Medical Marijuana Framework Takes Effect
Trulieve Cannabis Corp. (NYSE: TRLV) has received federal registrations from the Drug Enforcement Administration (DEA) for its medical marijuana dispensaries. The company announced Monday that it is among the first state-licensed operators approved under the new federal framework for medical marijuana. The DEA began issuing these registrations on October 30, in the first phase of the Attorney General’s April order.
Key Points
- Trulieve received DEA registrations for its medical marijuana dispensaries in the agency’s first round of approvals.
- The DEA began issuing federal registrations to qualifying state-licensed medical marijuana dispensaries on October 30.
- Trulieve applied in April, right after state-licensed medical marijuana moved to Schedule III under the Controlled Substances Act.
- The milestone strengthens Trulieve’s position in the PRISM Cannabis Index.
What the DEA Approved for Trulieve (NYSE: TRLV)
The registrations put Trulieve’s medical business under formal federal oversight for the first time. In April, the Attorney General’s order moved qualifying state-licensed medical marijuana activity to Schedule III and set up an expedited path for operators to register with the DEA. Trulieve filed its applications that same month. Now it holds some of the first registrations the agency has actually issued.
The registration process also covers more than retail. State-licensed manufacturers, distributors and testing laboratories can apply, too.
Founder and CEO Kim Rivers said the reclassification opens the door to clinical research and puts responsible operators on equal footing. She also thanked the DEA for its continued work with state-licensed medical cannabis companies as the framework rolls out.
Built for This Moment
Trulieve has spent most of 2026 positioning itself for this step. After rescheduling, the company restructured so that its consolidated business includes only medical marijuana operations. In June it reported 206 medical dispensaries backed by 3.5 million square feet of production capacity, all in Florida, Georgia, Pennsylvania and West Virginia.
That restructuring also helped Trulieve become the first U.S. cannabis company listed on the New York Stock Exchange, with trading under TRLV starting June 10. The Schedule III shift also removed the federal 280E tax burden from its medical operations, so those businesses can now take ordinary business deductions. In addition, Trulieve holds conditional medical license awards in Alabama and Texas.
PRISM MarketView has followed each turn in the rescheduling story, starting with cannabis stocks surging as Trump signaled support for rescheduling. Before the reclassification, Trulieve strengthened its balance sheet with a $60 million senior secured notes financing.
Why It Matters for the PRISM Cannabis Index
Federal registration changes what investors can expect from medical operators. Trulieve now combines a major-exchange listing, a medical-only footprint and DEA registrations, which no other U.S. plant-touching company has done. As a result, it sets the benchmark that rivals across the PRISM Cannabis Index will be measured against as they look at their own uplisting and registration plans.
There are still limits. These registrations are separate from the broader marijuana rescheduling proceeding, which is still under administrative review. Recreational marijuana, along with any activity outside the April order, remains under Schedule I controls.
What to Watch Next for Trulieve
The next catalysts are more DEA registrations across the industry, including for manufacturers, distributors and labs, and the outcome of the broader rescheduling review. For investors, the key questions are how fast Trulieve can turn federal standing into clinical research partnerships, banking access and growth in new markets like Texas. For more on how state policy is reshaping the sector, see PRISM MarketView’s look at how Texas’s hemp crackdown could boost larger cannabis names.
